Fenwick & West LLP represented Cervel Neurotech, Inc., a privately held company developing a novel, non-invasive and non-pharmacologic therapy for depression, pain and other conditions, in its recently announced $14.1 million equity financing. Existing investors D.E. Shaw Ventures and Aberdare Ventures participated in the round, with two new investors joining the equity syndicate and a credit facility with East West Bank completing the financing.
The company plans on utilizing the new funds to enable the continued demonstration of the highly differentiated nature of our platform for the treatment of psychiatric and neurologic conditions.
The Fenwick transaction team was led by corporate partner Stephen Graham; and corporate associates Andrew Albertson and Adam Andrews.